# Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)

> **NCT02244333** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 4575 (actual)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **DRUG:** ALNA®

## Key facts

- **NCT ID:** NCT02244333
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2004-07
- **Final completion:** —
- **Target enrollment:** 4575 (ACTUAL)
- **Last updated:** 2014-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02244333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02244333, "Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02244333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*